Skip to main content
Fig. 3 | Virology Journal

Fig. 3

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Fig. 3

Percentages of HLA-A*1101/EBV-LMP2-SSC-specific CD8+ T cells in patients at + 30, + 60, and + 90 days after haplo-HSCT and in healthy controls. Data are presented as the means ± standard deviations. The recovery of CD8+ T cells against EBV specific epitope LMP2-SSC as measured by pentamer technology. Four group are shown on the panel. The percentage of HLA-A*1101/EBV-LMP2-SSC-specific CD8+ T cells in patients at + 30, + 60, and + 90 days after haplo-HSCT and in healthy controls are presented

Back to article page

Virology Journal

ISSN: 1743-422X